G
Gene V. Wallenstein
Researcher at Pfizer
Publications - 84
Citations - 8118
Gene V. Wallenstein is an academic researcher from Pfizer. The author has contributed to research in topics: Tofacitinib & Janus kinase inhibitor. The author has an hindex of 33, co-authored 83 publications receiving 7137 citations. Previous affiliations of Gene V. Wallenstein include Harvard University & Florida Atlantic University.
Papers
More filters
Journal ArticleDOI
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann,Joel M. Kremer,John J. Cush,Hendrik Schulze-Koops,Carol A. Connell,John D. Bradley,David Gruben,Gene V. Wallenstein,Samuel H. Zwillich,Keith S. Kanik +9 more
TL;DR: In patients with active rheumatoid arthritis, tofacitinib monotherapy was associated with reductions in signs and symptoms of rheumatism and improvement in physical function and tofacit inib treatment wasassociated with elevations in low-density lipoprotein cholesterol levels and reductions in neutrophil counts.
Journal ArticleDOI
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
Ronald F van Vollenhoven,Roy Fleischmann,Stanley Cohen,Eun Bong Lee,Juan A. García Meijide,Sylke Wagner,Šárka Forejtová,Samuel H. Zwillich,David Gruben,Tamas Koncz,Gene V. Wallenstein,Sriram Krishnaswami,John D. Bradley,Bethanie Wilkinson +13 more
TL;DR: In patients with rheumatoid arthritis receiving background methotrexate, tofacitinib was significantly superior to placebo and was numerically similar to adalimumab in efficacy.
Journal ArticleDOI
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R Burmester,Ricardo Blanco,Christina Charles-Schoeman,Jürgen Wollenhaupt,Cristiano A. F. Zerbini,B. Benda,David Gruben,Gene V. Wallenstein,Sriram Krishnaswami,Samuel H. Zwillich,Tamas Koncz,Koshika Soma,John S. Bradley,Charles A Mebus +13 more
TL;DR: In this treatment-refractory population, tofacitinib with methotrexate had rapid and clinically meaningful improvements in signs and symptoms of rheumatoid arthritis and physical function over 6 months with manageable safety.
Journal ArticleDOI
Gamma frequency-range abnormalities to auditory stimulation in schizophrenia
Jun Soo Kwon,Jun Soo Kwon,Brian F. O'Donnell,Gene V. Wallenstein,Robert W. Greene,Yoshio Hirayasu,Paul G. Nestor,Michael E. Hasselmo,Geoffrey F. Potts,Martha E. Shenton,Robert W. McCarley +10 more
TL;DR: These data provide new information on selective deficits in early-stage sensory processing in schizophrenia, a failure to support the entrainment of intrinsic gamma-frequency oscillators.
Journal ArticleDOI
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
E.B. Lee,Roy Fleischmann,Stephen Hall,Bethanie Wilkinson,John D. Bradley,David Gruben,Tamas Koncz,Sriram Krishnaswami,Gene V. Wallenstein,Chuanbo Zang,Samuel H. Zwillich,Ronald F van Vollenhoven +11 more
TL;DR: Tofacitinib monotherapy was superior to methotrexate in reducing signs and symptoms of rheumatoid arthritis and inhibiting the progression of structural joint damage.